COVAXIN crosses half-way mark in phase 3 clinical trials with 13,000 volunteers

The Phase III human clinical trials of COVAXIN which began mid-November targeted to be done in 26,000 volunteers across India. This is India’s first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India.